Systemic therapy for sarcoidosis is reserved for organ-threatening disease, and laryngeal involvement necessitates treatment ...

ETX-19477 is a potent, selective inhibitor of poly (ADP-ribose) glycohydrolase (PARG), an enzyme that plays a role in the DNA ...

Intrapleural enzyme therapy (IET) improves outcomes in adult inpatients with complicated parapneumonic pleural effusion or empyema.

Both Phase 3 trials met all primary and secondary endpoints with high statistical significance in patients with moderate-to-severe plaque ...

Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering first-in-class therapeutics based on small-molecule inhibition of CLK/DYRK kinases, announced today that ...

Some clinicians are embracing transparency in response to patients’ questions about products hyped on social media; others ...

Gordian Bio, a biotechnology company pioneering large-scale in vivo functional genomics to unlock validated drug targets for ...

A research team provides an overview of how engineered probiotics—genetically modified beneficial microbes—are being transformed into living medicines capable of sensing disease, delivering therapies, ...

Coya Therapeutics, Inc. ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with ...

PALI-2108 is the first and only PDE4 inhibitor in development designed for targeted delivery to the terminal ileum and colon, addressing significant unmet needs in ulcerative colitis (UC) and fibroste ...

Ongoing clinical research at UNC could lead to a first-of-its-kind enzyme replacement therapy for Hunter syndrome, an ...

Successful management of denture-associated candidiasis relies heavily on mechanical disinfection rather than pharmacologic ...